IO Biotech to Present at the 45th Annual Cowen Health Care Conference
Presentation will include an update on the development and launch preparations of Cylembio™ (imsapepimut and etimupepimut, adjuvanted)NEW YORK, ...
Medscape1d
EV+P Benefit Continues in Metastatic Urothelial Cancer
PFS and OS benefits over chemotherapy were maintained for more than 2 years, and many patients had durable responses to ...
BioSpace2d
5 Pharma Powerhouses Facing Massive Patent Cliffs—And What They’re Doing About It
Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...
Merck wins EU nod for Welireg against two kidney cancer indications
Merck (NYSE:MRK) announced Tuesday that the European Commission approved its anti-cancer agent Welireg (belzutifan) as a ...
Cancer Vaccines Market on Track for Major Expansion in the 7MM Amid Immunotherapy Advancements, Predicts DelveInsight
The cancer vaccine market is anticipated to experience substantial growth in the coming years. This growth is driven by the rising number of cancer diagnoses, heightened awareness of cancer vaccines, ...
EQS-News: Formycon AG informs about recent developments in various biosimilar projects and invites to conference call
Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, Prime Standard) (“Formycon” or “the Company”) today provided an update on key developments across various biosimilar projects and invites ...
PipelineReview.com5d
Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201
PLANEGG-MARTINSRIED I Germany I 17, 2025 I The Executive Board of Formycon AG (FSE: FYB, Prime Standard) (“Company”) has decided today to prematurely ...